Europe is at a turning point for global competitiveness. As the life sciences landscape shifts rapidly, the choices made today will determine whether Europe restores its leadership in pharmaceutical innovation or continues to lose ground in areas like R&D investment, clinical trials, and timely patient access to breakthrough therapies. In an exclusive interview with Business Review, Stefan Oelrich, President of the European Federation of Pharmaceutical Industries and Associations (EFPIA),